Fangzhou Inc.

Fangzhou Inc.

HHKEX:6086
1.03
HKD
+0.01
(+0.98%)
942.10MMarket Cap
Mar 19Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.31
1.64
1.82
2.77
2.65
- -
Basic EPS, GAAP
-0.23
-0.29
-0.15
-0.88
0.01
- -
Free Cash Flow per Basic Share
-0.16
-0.04
0.01
0.02
0.05
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-1
-1.28
-1.42
0.1
0.11
0.21
Tangible Book Value per Share
-1
-1.28
-1.42
0.1
0.11
0.21
Basic Weighted Avg Shares
1,340
1,340
1,340
976
1,333
1,355
Sales/Revenue/Turnover
1,759
2,204
2,434
2,707
3,526
- -
Operating Margin (%)
-12.75
-5.74
-1.1
-27.66
0.33
- -
Depreciation Expense
13
17
20
24
21
- -
Net Income, GAAP
-304
-383
-197
-855
12
- -
Effective Tax Rate (%)
- -
- -
- -
- -
1.61
- -
Profit Margin (%)
-17.28
-17.39
-8.08
-31.58
0.34
- -
Working Capital
- -
-2
-15
107
128
267
LT Debt
8
14
29
31
16
9
Total Equity
-1,340
-1,710
-1,901
132
154
296
Return on Invested Capital (%)
- -
- -
- -
- -
6.61
- -
Return on Capital (%)
- -
- -
- -
- -
7.1
- -
Return on Common Equity (%)
- -
- -
- -
- -
8.29
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
15
19
14
LT Borrowings
- -
- -
- -
LT Finance Leases
21
16
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,340
1,340
1,385
Market Capitalization
4,403
2,710
815

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
724
772
935
Cash, Cash Equivalents & STI
294
314
419
Accounts Receivable, Net
49
62
52
Inventories
203
180
213
Total Current Liabilities
597
644
668
Payables & Accruals
- -
- -
- -
ST Debt
15
19
14
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
16.72%
Free Cash Flow
- -
- -
330.25%
Net Income, GAAP
- -
- -
-101.38%
Sales/Revenue/Turnover
- -
- -
30.24%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2,707
2025
- -
- -
3,526
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.88
2025
- -
- -
0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Hai Jiao Wang
Full Time Employees
494
Sector
Retail trade
Industry
Drugstore chains
Address
Building S, Kehui Jingu Guangzhou GD China 510663
IPO Date
Jul 9, 2024
Website
jianke.com
Business
Fangzhou Inc. (6086.HK) operates as an investment holding company that provides online chronic disease management services in China through its Jianke Platform, focusing on patients with conditions such as hypertension, cardiovascular and respiratory diseases; the company offers comprehensive medical services including follow-up physician consultations, e-prescriptions, prescription refills and home delivery via its hospital-to-home (H2H) telemedicine platform supported by nearly 223,000 registered physicians (59% from Class III hospitals); online retail pharmacy services encompassing nearly 215,000 drug SKUs (62% prescription medications), healthcare products and pharmaceutical sales through online and minimal offline channels; wholesale of pharmaceutical products to third parties; and customized content and marketing solutions such as academic and patient community services, live streaming (over 11,000 sessions in 2024), search engine optimization, medical surveys and distributor data integration for pharmaceutical companies. Founded in 2015 and headquartered in Guangzhou, China, at Floor 1-2, 4th Street, Building S, Kehui Jingu, No. 99 Science Avenue, the company serves a platform with 49.2 million registered users and 10.1 million average monthly active users as of December 31, 2024, primarily targeting chronic disease patients and healthcare providers across China with a robust supply chain linking over 1,500 suppliers and 900 pharmaceutical firms. Fangzhou Inc. reports revenue across these segments totaling RMB2.71 billion for the year ended December 31, 2024 (up 11.2% year-over-year), with online retail pharmacy at RMB1.40 billion (8.3% growth), comprehensive medical services at RMB647 million, wholesale at RMB551 million (728.5% surge) and customized content/marketing at RMB105 million (20.7% rise); it achieved adjusted net profit of RMB17 million (up 139%) despite statutory losses from share-based compensation. Recent developments include integration with China's social healthcare insurance for online reimbursements and dual-channel prescriptions via its Qishi Internet Hospital and Fangzhou Jianke Medical Insurance Assistant Mini Program; strategic partnerships with Guangzhou Baiyunshan Pharmaceutical, Bristol Myers Squibb, Innovent Biologics, Zhejiang Otsuka Pharmaceutical and Tencent Healthcare for AI-enhanced chronic disease management; rollout of AI applications like AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant and AI-Powered Search powered by a proprietary large language model; expansion of physician recruitment via sales force automation and social CRM systems; and honors such as 2024 Guangdong AI Catalyst recognition, national high-tech enterprise status for subsidiary Fangyixing and Top 10 AI+Healthcare listing. The company employs 488 staff as of December 31, 2024, and maintains a repeat purchase rate of 84.7% among paying users, with prescription drugs comprising 81.3% of GMV.